Company / Return on Equity (ROE)
Amneal Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
66.5%
FY2023
5-year range
-167.5% / 66.5%
FY2019-FY2023
Trend
+173.4%
vs FY2022
Sector context
#8 of 190
Health Care
What the data says
Among 190 Health Care companies, Amneal Pharmaceuticals, Inc. is in the top 4% for return on equity (roe). Improved from -167.5% to 66.5% over the past 2 years.
Based on SEC 10-K filings.
66.5% in FY2023 with a 5-year CAGR of +66.5%. Top quartile in the Health Care sector.
Improved from -167.5% to 66.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +73.0pp
- 5-Year Change
- +66.5pp
- 10-Year Change
- -
Sector benchmark
Top 4% in Health CareTop 4% of 190This company 66.5% Sector average -50.3%
▼
+232.2% above sector average
Key checks
Key Insights
- In FY2023, return on equity (roe) increased 173.4% year-over-year.
- Currently 116.9pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | 66.5% | +173.4% |
| FY2022 | -90.7% | +45.9% |
| FY2021 | -167.5% | -2473.0% |
| FY2020 | -6.5% | - |
| FY2019 | 0.0% | - |
| FY2018 | 0.0% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026